Geode Capital Management
CLYM

Geode Capital Management’s Climb Bio CLYM Stock Holding History

Geode Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.15M Buy
312,999
+2,243
+0.7% +$12.9K ﹤0.01% 3091
2025
Q4 		$1.24M Sell
310,756
-965
-0.3% -$2.32K ﹤0.01% 3313
2025
Q3 		$627K Hold
311,721
– – ﹤0.01% 3533
2025
Q2 		$387K Sell
311,721
-362,090
-54% -$451K ﹤0.01% 3636
2025
Q1 		$822K Buy
673,811
+12,980
+2% +$21.1K ﹤0.01% 3371
2024
Q4 		$1.19M Buy
660,831
+9,534
+1% +$34.5K ﹤0.01% 3304
2024
Q3 		$3.32M Buy
651,297
+479,700
+280% +$3.39M ﹤0.01% 2952
2024
Q2 		$1.22M Buy
171,597
+104,971
+158% +$699K ﹤0.01% 3236
2024
Q1 		$183K Hold
66,626
– – ﹤0.01% 3972
2023
Q4 		$179K Hold
66,626
– – ﹤0.01% 3983
2023
Q3 		$176K Buy
66,626
+2,612
+4% +$7.12K ﹤0.01% 4036
2023
Q2 		$179K Hold
64,014
– – ﹤0.01% 4091
2023
Q1 		$186K Hold
64,014
– – ﹤0.01% 4088
2022
Q4 		$229K Sell
64,014
-125
-0.2% -$371 ﹤0.01% 4026
2022
Q3 		$207K Hold
64,139
– – ﹤0.01% 4191
2022
Q2 		$193K Sell
64,139
-48,882
-43% -$231K ﹤0.01% 4291
2022
Q1 		$948K Sell
113,021
-2,651
-2% -$24.7K ﹤0.01% 3643
2021
Q4 		$1.21M Buy
115,672
+38,768
+50% +$578K ﹤0.01% 3622
2021
Q3 		$1.38M Buy
+76,904
New +$1.59M ﹤0.01% 3524

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Geode Capital Management's CLYM Position: Q1 2026 in Review

Geode Capital Management increased its Climb Bio (CLYM) stake by 0.72% in Q1 2026, buying an estimated $12.9K and bringing the position to 312,999 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3091.

Geode Capital Management first reported a position in CLYM in Q3 2021 and has held it in 19 quarters since. The position peaked at $3.32M in Q3 2024. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Geode Capital Management held 312,999 shares of Climb Bio worth $2.15M as of Q1 2026.
  • Geode Capital Management bought 2,243 Climb Bio shares in Q1 2026, an estimated $12.9K.
  • Climb Bio made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3091 holding.
  • Geode Capital Management first reported a position in Climb Bio in Q3 2021 and has held it in 19 quarters since.
  • Geode Capital Management's Climb Bio position peaked at $3.32M in Q3 2024.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.